Natural 'decoy receptor' protects against inflammatory bowel disease, research reveals

In a study published in Nature Immunology on January 6, a research team led by Prof. Qian Youcun from the Shanghai Institute ...

Idorsia Pharmaceuticals Ltd: Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland - January 6, 2026Idorsia ...
The Manila Times

Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indicationsAllschwil, Switzerland - January 6, 2026 ...
eLife

Separating selection from mutation in antibody language models

This important study introduces a new biology-informed strategy for deep learning models aiming to predict mutational effects in antibody sequences. It provides solid evidence that separating ...
Longevity LIVE

Do Genes Hold The Secret to Longevity?

We explore the idea of 'longevity genes' and whether being blessed with a FOXO3 variant which will translate to a longer and ...
eLife

Translational reading frame determines the pathogenicity of C-terminal frameshift deletions in MeCP2: an alternative therapeutic approach

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...
EurekAlert!

Understanding pain heterogeneity in osteoarthritis patients: A narrative review

Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...